Klemastin: Perbedaan antara revisi
Konten dihapus Konten ditambahkan
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
Tidak ada ringkasan suntingan Tag: Suntingan perangkat seluler Suntingan peramban seluler Suntingan seluler lanjutan |
||
Baris 84:
==Penelitian==
Klemastin telah dipelajari karena potensinya untuk mengobati beberapa gangguan kejiwaan dan neurologis, termasuk kemungkinan meningkatkan remielinasi dan perbaikan mielin dalam kondisi seperti [[sklerosis multipel]] (MS).<ref name="pmid37840769">{{cite journal |vauthors=Jiang S, Wang X, Cao T, Kang R, Huang L |title=Insights on therapeutic potential of clemastine in neurological disorders |journal=Frontiers in Molecular Neuroscience |volume=16 |pages=1279985 |date=2023 |pmid=37840769 |pmc=10568021 |doi=10.3389/fnmol.2023.1279985|doi-access=free }}</ref><ref name="Leigh 2023">{{cite web |last=Leigh |first=Suzanne |title=Can this Medication Reverse MS? Brain Biomarker Shows It Can |website=UCSF |date=12 June 2023 |url=https://www.ucsf.edu/news/2023/06/425566/can-medication-reverse-ms-brain-biomarker-shows-it-can |access-date=17 April 2024}}</ref> Uji klinis fase II awal menunjukkan harapan untuk meningkatkan remielinasi pada pasien dengan MS, dengan klemastin meningkatkan kecepatan konduksi saraf di saraf optik.<ref name="pmid38389586">{{cite journal |vauthors=Riboni-Verri G, Chen BS, McMurran CE, Halliwell GJ, Brown JW, Coles AJ, Cunniffe NG |title=Visual outcome measures in clinical trials of remyelinating drugs |journal=BMJ Neurology Open |volume=6 |issue=1 |pages=e000560 |date=2024 |pmid=38389586 |pmc=10882304 |doi=10.1136/bmjno-2023-000560}}</ref><ref name="pmid32145678">{{cite journal |vauthors=Moghaddasi M, Nabovvati M, Koushki A, Soltansanjari M, Sardarinia M, Mohebi N, Rabani S |title=Randomized control trial of evaluation of Clemastine effects on visual evoked potential, nerve fiber layer and ganglion cell layer complex in patients with optic neuritis |journal=Clinical Neurology and Neurosurgery |volume=193 |pages=105741 |date=June 2020 |pmid=32145678 |doi=10.1016/j.clineuro.2020.105741 }}</ref> Namun, uji klinis (TRAP-MS) dihentikan pada awal tahun 2024 setelah peneliti menemukan perkembangan kecacatan terjadi pada tingkat yang jauh lebih cepat daripada yang diantisipasi pada tiga peserta dengan MS yang menerima klemastin.<ref name="Ciccone 2024">{{cite web |last=Ciccone |first=Isabella |title=Clemastine Arm of TRAP-MS Trial Halted Following Increased Disability Accumulation in Progressive Multiple Sclerosis |website=NeurologyLive |date=2 March 2024 |url=https://www.neurologylive.com/view/clemastine-arm-trap-ms-trial-halted-following-increased-disability-accumulation-progressive-ms |access-date=17 April 2024}}</ref><ref name="Dotinga 2024">{{cite web |last=Dotinga |first=Randy |title=Clemastine Tied to Worsening Symptoms in Multidrug MS Trial |website=Medscape |date=14 March 2024 |url=https://www.medscape.com/viewarticle/unexpected-finding-clemastine-fumarate-linked-worsening-2024a10004ss |access-date=17 April 2024}}</ref><ref name="Maia 2024">{{cite web |last=Maia |first=Margarida |title=ACTRIMS 2024: An antihistamine may speed MS disease progression |website=Multiple Sclerosis News Today |date=7 March 2024 |url=https://multiplesclerosisnewstoday.com/news-posts/2024/03/07/actrims-2024-antihistamine-may-speed-ms-disease-progression/ |access-date=17 April 2024}}</ref>
==Referensi==
{{Reflist}}
| |||